Current Atherosclerosis Reports

, Volume 14, Issue 5, pp 391–393 | Cite as

A Tail with a Thorn in it: Second-Generation Antipsychotics Hand in Hand with Statins

Invited Commentary
  • 139 Downloads

Keywords

Metabolic syndrome Atypical antipsychotics statins Schizophrenia 

Notes

Disclosure

R. Durtst: none. E. Leitersdorf: Board membership, consultancy and honoraria received from Roche, Merck, and Novartis, payment for the development of educational presentations from Roche and Merck.

References

  1. 1.
    Health Niom. Schizophrenia. Available at: http://www.nimh.nih.gov/statistics/1SCHIZ.shtml. Accessed 15 April 2012.
  2. 2.
    Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry. 2011;72 Suppl 1:4–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2004;10:79–104.CrossRefGoogle Scholar
  4. 4.
    Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.PubMedCrossRefGoogle Scholar
  5. 5.
    Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St. Sauver J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950–2005. Schizophr Res. 2008;98:287–94.PubMedCrossRefGoogle Scholar
  6. 6.
    J. Parks DS, Singer P, Foti M. Morbidity and mortality in people with serious mental illness.National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council, Alexandria, VA 22314. 2006. Available at: http://www.nasmhpd.org/general_files/publications/med_directors_pubs/Technical%20Report%20on%20Morbidity%20and%20Mortaility%20-%20Final%2011-06.pdf. Accessed 15 April 2012.
  7. 7.
    Tsuang MT. Suicide in Schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Arch Gen Psychiatry. 1978;35:153–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Tsuang MT, Woolson RF, Fleming JA. Premature deaths in schizophrenia and affective disorders: an analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry. 1980;37:979–83.PubMedCrossRefGoogle Scholar
  9. 9.
    de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76:135–57.PubMedCrossRefGoogle Scholar
  10. 10.
    Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz NL. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr Res. 2005;79:323–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of 10-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45–53.PubMedCrossRefGoogle Scholar
  12. 12.
    Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, et al. Olanzapine vs ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005;162:1879–87.PubMedCrossRefGoogle Scholar
  13. 13.
    Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine vs olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43:138–46.PubMedCrossRefGoogle Scholar
  14. 14.
    Grootens KP, van Veelen NM, Peuskens J, Sabbe BG, Thys E, Buitelaar JK, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull. 2011;37:352–61.PubMedCrossRefGoogle Scholar
  15. 15.
    Merck Pulls Arthritis Drug Vioxx from Market NPR; 2004. Available at: http://www.npr.org/templates/story/story.php?storyId=4054991. Accessed 15 April 2012.
  16. 16.
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–102.PubMedCrossRefGoogle Scholar
  18. 18.
    Rofecoxib. Wikipedia; 2009. Available at: http://en.wikipedia.org/wiki/Rofecoxib. Accessed 15 April 2012.
  19. 19.
    Smith Jr SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432–46.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Center for Research Prevention and Treatment of AtherosclerosisHadassah Hebrew University Medical CenterJerusalemIsrael
  2. 2.Cardiology DepartmentHadassah Hebrew University Medical CenterJerusalemIsrael

Personalised recommendations